The Sept. 21 announcement states that Gadopiclenol Injection—a highly stable macrocyclic gadolinium-based contrast agent—is approved for use in adult and pediatric patients aged 2 years and older during MRI exams.

For specificity—a metric that has been somewhat unpredictable in breast MRI and CEM—the scoring system performed significantly better than BI-RADS.

According to the FDA’s most recent update, some presentations will remain out of stock or backordered until January 2023. 

A new article published by the Radiological Society of North America shares valuable commentary from experts in the field regarding how the medical industry can prepare for supply shortages in the future. 

The Aug. 29 statement indicates that non-radiologist physicians, advanced practice providers and registered nurses can oversee intravenous CT and MRI contrast administration at accredited imaging centers.

This week in AJR, experts from a large, multisite health system detailed their efforts to preserve contrast supplies by implementing electronic health record (EHR) order entry-based interventions.

"Ultimately, long-term studies are vital to parse out whether the absence of iodinated contrast media greatly affected patient outcomes or if we have been overdependent on ICM unnecessarily.” 

Bracco Diagnostics, Inc has been given the go ahead by the U.S. Food and Drug Administration to temporarily import Iomeron (iomeprol injection) into the U.S. market amid the ongoing iodinated contrast media shortage.